Amendment No. 2 to the Respiratory Diseases Research Collaboration and License AgreementRespiratory Diseases Research Collaboration and License Agreement • August 7th, 2014 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This Amendment No. 2 to the Respiratory Diseases Research Collaboration and License Agreement (this “Amendment No. 2”), effective as of April 9, 2014 (the “Amendment No. 2 Effective Date”), is made by and between Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080 (“FivePrime”).
Respiratory Diseases Research Collaboration and License AgreementRespiratory Diseases Research Collaboration and License Agreement • March 11th, 2016 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This Amendment No. 3 to the Respiratory Diseases Research Collaboration and License Agreement, effective as of January 26, 2016 (this “Amendment No. 3”), is made by and between Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, England (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080, USA (“FivePrime”).
RESPIRATORY DISEASES RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Glaxo Group Limited and Five Prime Therapeutics, Inc.Respiratory Diseases Research Collaboration and License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
and brings tremendous expertise to the collaboration. Our existing GSK alliance to discover products for skeletal muscle disorders, which was recently expanded last year, is making great progress, so we are extremely pleased to enter into this additional collaboration.” said Lewis T. “Rusty” Williams, MD, PhD, Founder, President and CEO of FivePrime.
Amendment No. 1 to the Respiratory Diseases Research Collaboration and License AgreementRespiratory Diseases Research Collaboration and License Agreement • July 26th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This Amendment No. 1 to the Respiratory Diseases Research Collaboration and License Agreement (this “Amendment No. 1”), effective as of the August 9, 2012 (the “Amendment No. 1 Effective Date”), is made by and between Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080 (“FivePrime”).
